A Form 4 filed with the SEC on August 13, 2026, discloses that Michael R. Hayden, a director of AbCellera Biologics Inc. (NASDAQ:ABCL), reported a charitable donation of 50,000 common shares on August 11, 2026.
Key Highlights
- Reporting person: Michael R. Hayden, identified as a Director of AbCellera Biologics Inc.
- Transaction: 50,000 common shares disposed of via transaction code "G" (gift) at a price of $0 on August 11, 2026.
- Donating entity: The shares were donated by Genworks 2 Consulting, Inc., according to the filing's footnote.
- Post-transaction indirect holdings: 1,273,397 common shares held indirectly through Genworks 2 Consulting, Inc. following the transaction.
- Additional indirect holdings: 118,245 common shares held indirectly by spouse, as reported in the filing.
- Disclaimer: The reporting person disclaims beneficial ownership of shares held by Genworks 2 Consulting, Inc., "except to the extent of his indirect pecuniary interest, if any, therein."
Hayden Reports Charitable Share Donation Through Consulting Entity
According to the Form 4 filed on August 13, 2026, Michael R. Hayden, a director at AbCellera Biologics Inc., reported a disposition of 50,000 common shares of NASDAQ:ABCL. The filing classifies the transaction with code "G," and footnote 1 states: "This transaction represents a charitable donation of 50,000 common shares made by Genworks 2 Consulting, Inc. on August 11, 2026." The shares were disposed of at a price of $0.
The filing further discloses, in footnote 2, that the shares held by Genworks 2 Consulting, Inc. are subject to sole voting and investment power by the reporting person's spouse. Hayden disclaims beneficial ownership of those securities "except to the extent of his indirect pecuniary interest, if any, therein." Following the reported transaction, Hayden's indirect beneficial ownership through Genworks 2 Consulting, Inc. stands at 1,273,397 common shares, with an additional 118,245 common shares held indirectly by his spouse.
No derivative securities were reported in Table II of the filing. The Form 4 was signed by Tryn Stimart as attorney-in-fact, dated August 13, 2026, and was filed as a single reporting person filing with no amendment noted.
What Was Disclosed
The filing reports a charitable donation of 50,000 AbCellera Biologics common shares by Genworks 2 Consulting, Inc. on August 11, 2026, with Director Michael R. Hayden's indirect beneficial ownership in that entity standing at 1,273,397 shares after the transaction.




Please wait processing your request...